Luminex Buys Nanosphere, Citing Infectious Disease Strength
This article was originally published in Clinica
Diagnostics platform and assay-maker Luminex has agreed to buy molecular diagnostics specialists Nanosphere for a total cash outlay of $72m, the companies announced May 16.
You may also be interested in...
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
In this week’s podcast, Marion Webb reviews her interview with Glooko CEO Russ Johannesson and Reed Miller explains how Boston Scientific is restructuring its transcatheter aortic valve business.